Print health ad spending rises in January; Novo program fights urban diabetes;

> Print health ad spending in the U.S. totaled $45 million in January, a 7% year-on-year increase. Report

> Novo Nordisk ($NVO) has launched "Cities Changing Diabetes," a partnership program to fight urban diabetes. Release

> BioAlliance Pharma has fired Oravig marketing partner Vestiq Pharmaceutical and has updated its marketing partnership for Loramyc. Release

> Stallergenes has won FDA approval for Oralair, an immunotherapy allergy tablet that will be marketed by Greer. Release

> With Sanofi Oncology's ($SNY) "Strollin' Colon" display, onlookers can walk through a giant inflatable colon and learn about the colorectal cancer screening process. More

> Johnson & Johnson Middle East ($JNJ) has teamed up with Impact BBDO Dubai to create a grandparents-only app and digital photo frame that receives and displays photos of grandchildren. More

> Specialty pharma Clinigen Group has acquired Savene, an oncology support therapy, from SpePharm AG. Release

And Finally... What is a patent troll? Congress, courts try to find out. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?